Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, PO Box 281, 171 77 Stockholm, Sweden.
Breast Cancer Res Treat. 2010 Jun;121(3):679-83. doi: 10.1007/s10549-009-0615-7. Epub 2009 Nov 6.
Studies from Western countries have found evidence of a recent decline in breast cancer incidence rates in postmenopausal women, findings which have been hypothesized to reflect a reduced use of hormonal replacement therapy (HRT). We examined breast cancer incidence trends in Sweden between 1997 and 2007, a period characterized by a drop in the use of HRT. Incidence trends were assessed using data from three population-based Regional Clinical Registries on breast cancer covering 2/3 of the Swedish population. Information on HRT sales was obtained from national pharmacy data. The prevalence of HRT use in age group 50-59 years decreased from a peak of 36% in 1999 to 27% in 2002 and further to 9% in 2007. Incidence rates of breast cancer in women 50 years and older increased between 1997 and 2003. A significant decrease in incidence between 2003 and 2007 was confined to women 50-59 years of age, the group in which the prevalence of HRT use has been highest and the decrease in use most pronounced. As opposed to the immediate effects reported from the United States and other regions, there was a time lag between the drop in HRT use and clear reductions in breast cancer incidence. This may reflect between country differences with regard to types of HRT used, and the rate, magnitude and pattern of change in use. The present findings give further support to the notion that HRT use is a driver of breast cancer incidence trends on the population level.
西方国家的研究已经发现了绝经后妇女乳腺癌发病率近期下降的证据,这些发现被假设反映了激素替代疗法(HRT)使用的减少。我们研究了瑞典在 1997 年至 2007 年间乳腺癌发病率的趋势,这一时期 HRT 的使用量有所下降。发病率趋势是通过覆盖瑞典人口 2/3 的三个基于人群的区域性临床登记处的乳腺癌数据进行评估的。HRT 使用的信息来自全国药房数据。50-59 岁年龄组中 HRT 使用的流行率从 1999 年的 36%的峰值下降到 2002 年的 27%,进一步下降到 2007 年的 9%。50 岁及以上女性的乳腺癌发病率在 1997 年至 2003 年间增加。2003 年至 2007 年间发病率的显著下降仅限于 50-59 岁年龄组,该组 HRT 使用的流行率最高,使用量下降最为明显。与美国和其他地区报告的即时影响相反,HRT 使用量下降与乳腺癌发病率明显下降之间存在时间滞后。这可能反映了各国之间在使用的 HRT 类型、使用的变化速度、幅度和模式方面的差异。本研究结果进一步支持了 HRT 使用是人群水平乳腺癌发病率趋势的驱动因素这一观点。